Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies

Steven R. Deitcher

doi:10.1055/s-2003-40963

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(3): 247-258
DOI: 10.1055/s-2003-40963

Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies

Steven R. Deitcher

Head, Section of Hematology Coagulation Medicine Department of Hematology Medical Oncology Director Clinical Thrombosis Vascular Research Section of Vascular Medicine Department of Cardiovascular Medicine. The Cleveland Clinic Foundation Cleveland Ohio

Abstract

ABSTRACT

Venous thromboembolic disease (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), is an underdiagnosed and underappreciated clinical problem in cancer patients that results in significant patient morbidity and mortality. Standard treatment practices, including the use of intravenous unfractionated heparin (UFH) for initial anticoagulation, the use of oral warfarin for chronic anticoagulation, and the prescription of only 3 to 6 months total therapy, may not be optimal in the setting of active cancer and ongoing anticancer therapy. Challenges of VTE management in cancer patients include heparin resistance because of excess circulating acute phase proteins, increased recurrence rates during warfarin therapy (target international normalized ratio 2 to 3), limited venous access to support therapeutic monitoring, and increased bleeding rates during anticoagulation. Bleeding during anticoagulation is of particular concern in patients with disease- or chemotherapy-related thrombocytopenia, central nervous system involvement with cancer, and recent surgical intervention. Low-molecular-weight heparins (LMWHs) have been shown to be equally effective and safe for initial anticoagulation compared with UFH and have gained popularity, especially in the setting of VTE in cancer. LMWHs have the advantage of less nonspecific protein binding, subcutaneous weight-based dosing without the need for monitoring in most cases, and less heparin-induced thrombocytopenia. Recent clinical trials have shown LMWHs are at least as effective as oral warfarin for long-term anticoagulation in cancer patients. Interest in LMWHs and several new classes of parenteral and oral anticoagulants extends beyond the primary and secondary prevention of VTE and includes antiangiogenesis, metastasis prevention, and survival prolongation.

KEYWORDS

Cancer - thrombosis - heparin - warfarin - hypercoagulability

Full Text

References

REFERENCES

1 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica . 1999; 84 437-445
2 Brill-Edwards P, Ginsberg J S, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med . 1993; 119 104-109
3 Kakkar V V, Howe C T, Nicolaides A N, Renney J T, Clarke M B. Deep vein thrombosis of the leg. Is there a “high risk” group?. Am J Surg . 1970; 120 527-530
4 Walsh J J, Bonnar J, Wright F W. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labeled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw . 1974; 81 311-316
5 Piccioli A, Prandoni P, Ewenstein B M, Goldhaber S Z. Cancer and venous thromboembolism. Am Heart J . 1996; 132 850-855
6 Gomes M PV, Deitcher S R. Diagnosis of venous thromboembolic disease in cancer patients. Oncology . 2003; 17 126-139
7 Sorensen H T, Mellemkjaer L, Steffensen F H, Olsen J H, Nielsen G L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med . 1998; 338 1169-1173
8 Deitcher S R, Goldman C K, Ruiter K. Vascular endothelial growth factor (VEGF) levels in patients with idiopathic acute proximal deep venous thrombosis (Abst). Thromb Haemost . 2001; 86(Suppl) P1517
9 Levitan N, Dowlati A, Remick S C. et al . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine . 1999; 78 285-291
10 Ottinger H, Belka C, Kozole G. et al . Deep venous thrombosis and pulmonary embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol . 1995; 54 186-194
11 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost . 1997; 78 33-136
12 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost . 1993; 69 205-213
13 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol . 2001; 73 137-144
14 Gordon S. Cancer cell procoagulants and their implications. Hematol Oncol Clin North Am . 1992; 6 1359-1374
15 Rickles F R, Hair G A, Zeff R A, Lee E, Bona R D. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost . 1995; 74 391-395
16 Bevilacqua M P, Pober J S, Majeau G R. et al . Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA . 1996; 83 4533-4537
17 Deitcher S R, Carman T L, Sheikj M, Gomes M. Hypercoagulable syndromes: evaluation and management strategies in acute limb ischemia. Semin Vasc Surg . 2001; 14 74-85
18 Deitcher S R, Lucore C, Eisenberg P R. Impaired resolution of a massive pulmonary embolus associated with an impaired fibrinolytic response. Am J Med . 1994; 96 483-484
19 Deitcher S R, Erban J K, Limentani S A. Acquired free protein S deficiency asociated with multiple myeloma. Am J Hematol . 1996; 51 319-323
20 Anderson A J, Krasnow S H, Boyer M W. et al . Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest . 1989; 95 71-75
21 Bona R D. Thrombotic complication of central catheters in cancer patients. Semin Thromb Hemost . 1999; 25 147-157
22 Gould J R, Carloss H W, Skinner W L. Groshong catheter-associated subclavian venous thrombosis. Am J Med . 1993; 95 419-423
23 Kee S T, Kinoshita L, Razavi M K. et al . Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology . 1998; 206 187-193
24 Patel V, Igwebe T, Mast H, Karetzky M S. Superior vena cava syndrome; current concepts of management. N Engl J Med . 1995; 92 245-248
25 Prandoni P, Polistena P, Bernardi E. et al . Upper extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med . 1997; 157 57-62
26 Raad I I, Luna M, Khalil S A. et al . The relationship between the thrombotic and infectious complications of central venous catheters. JAMA . 1994; 271 1014-1016
27 Goodnough L T, Saito H, Manni A, Jones P K, Pearson O H. Increased incidence of thromboembolism in stage-4 breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer . 1984; 54 1264-1268
28 Gail M H, Costantino J P, Bryant J. et al . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst . 1999; 91 1829-1846
29 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol . 1991; 9 286-294
30 Levine M N, Gent M, Hirsh J. et al . The thrombogenic effect of anticancer drug therapy in women with stage-2 breast cancer. N Engl J Med . 1988; 318 404-407
31 Pritchard K I, Paterson A H, Paul N A. et al . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol . 1996; 14 2731-2737
32 Zangari M, Siegel E, Anaissie E. et al . Risk factors for deep vein thrombosis in a large group of myeloma patients treated with thalidomide: The Arkansas Experience (Abst). Blood . 2001; 98 161a
33 Deitcher S R, Carman T L. Deep venous thrombosis and pulmonary embolism. Curr Treatment Options Cardiovasc Med . 2002; 4 223-238
34 Scates S M. Diagnosis and treatment of cancer-related thrombosis. Hematol Oncol Clin North Am . 1992; 6 1329-1339
35 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med . 2001; 344 626-631
36 Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer . 1987; 59 983-985
37 Heit J A, Mohr D N, Silverstein M D. et al . Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based chohort study. Arch Intern Med . 2000; 160 761-768
38 Hansson P O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med . 2000; 160 769-774
39 Prandoni P, Lensing A W, Cogo A. et al . The long term clinical course of acute deep venous thrombosis. Ann Intern Med . 1996; 125 1-7
40 Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost . 1997; 78 141-144
41 Prandoni P, Lensing A W, Piccioli A. et al . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood . 2002; 100 3484-3488
42 Bona R D, Sivjee K Y, Hickey A D, Wallace S B, Wajcs S B. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost . 1995; 74 1055-1058
43 Bona R D, Hickey A D, Wallace D M. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost . 1997; 78 137-140
44 Hutten B A, Prins M H, Gent M. et al . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol . 2000; 8 3078-3083
45 Levine M N, Hirsh J, Gent M. et al . A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med . 1994; 154 49-56
46 Hirsh J, Warkentin T W, Shaughnessy S G. et al . Heparin and low-molecular-weight heparin; mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest . 2001; 119(Suppl) 64S-94S
47 Chan A, Woodruff R K. Complications and failure of anticoagulation therapy in treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med . 1992; 22 119-122
48 Deitcher S R. Interpretation of the international normalized ratio in patients with liver disease. Lancet . 2002; 359 47-48
49 Hirsh J, Dalen J E, Anderson D. et al . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest . 2001; 119(Suppl) 8S-21S
50 Wells P S, Holbrook A M, Crowther N R. et al . The interaction of warfarin with drugs and food: a critical review of the literature. Ann Intern Med . 1994; 121 676-683
51 Deitcher S R, Carman T L. Heparin induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med . 2001; 6 113-119
52 Levine M N, Lee A Y, Baker R I. et al . A randomized trial of long-term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism (Abstract 298). Blood . 2002; 100 82a
53 Deitcher S R, Kessler C M, Merli G, Rigas J, Lyons R M, Cort S. Secondary prevention of venous thromboembolic events in patients with active malignancy: A randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. American Society of Clinical Oncology. 2003;
54 Beyth R J, Quinn L M, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding risk outpatients treated with warfarin. Am J Med . 1998; 105 91-99
55 Levine M N, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest . 2001; 119(Suppl) 108S-121S
56 Gitter M J, Jaeger T M, Petterson T M, Gersh M D, Silverstein M D. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc . 1995; 70 725-733
57 Wester J PJ, de Valk W H, Nieuwenhuis H K. et al . Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost . 1996; 76 682-688
58 Melissari E, Parker C J, Wilson N V. et al . Use of low molecular weight heparin in pregnancy. Thromb Haemost . 1992; 68 652-656
59 Sanson B-J, Lensing A W, Prins M H. et al . Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost . 1999; 81 668-672
60 Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol . 1997; 176 1062-1068
61 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood . 1995; 86 1368-1373
62 Muir J M, Hirsh J, Weitz J I. et al . A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood . 1997; 89 3236-3242
63 Bhandari M, Hirsh J, Weitz J. et al . The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost . 1998; 80 413-417
64 Carman T L, Kanner A A, Barnett G H, Deitcher S R. Neurosurgery thromboprophylaxis following tumor surgery: a survey. South Med J . 2003; 96 17-22
65 Altschuler E, Moosa H, Selker R G, Vertosick F T. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery . 1990; 27 74-77
66 Choucair A K, Silver P, Levin V A. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg . 1987; 66 357-358
67 Norris L K, Grossman S A. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol . 1994; 22 127-137
68 Olin J W, Young J R, Graor R A. et al . Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Arch Intern Med . 1987; 147 2177-2179
69 Ruff R L, Posner J B. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol . 1983; 13 334-336
70 Schiff D, DeAngelis L M. Therapy of venous thromboembolism in patients with brain metastases. Cancer . 1994; 73 493-498
71 Levine M, Gent M, Hirsch J. et al . A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med . 1996; 334 677-681
72 Koopman M M, Prandoni P, Piovella F. et al . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med . 1996; 334 682-687
73 Hull R D, Raskob G L, Pineo G F. et al . Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med . 1992; 326 975-982
74 Lindmarker P, Holmstrom M, Granqvist S. et al . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost . 1994; 72 186-190
75 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med . 1997; 337 657-662
76 Weitz J I. Low molecular weight heparins. N Engl J Med . 1995; 337 688-698
77 Warkentin T E, Levine M N, Hirsh J. et al . Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
78 Lensing A W, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med . 1995; 155 601-607
79 Siragusa S, Cosmi B, Piovella, Hirsh J, Ginsberg J S. Low molecular weight heparins and unfractionated heparin in the treatment of patient with acute venous thromboembolism; results of a meta-analysis. Am J Med . 1996; 100 269-277
80 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trails. Ann Intern Med . 1999; 130 800-809
81 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med . 2000; 160 181-188
82 Green D, Hull R D, Brant R, Pineo G F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet . 1992; 339 1476
83 Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone. Science . 1983; 221 719-725
84 Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis . 1993; 23(Suppl) 141-149
85 Hyers T M, Agnelli A, Hull R D. et al . Antithrombotic therapy for venous thromboembolic disease. Chest . 2001; 119(Suppl) 176S-193S
86 Anand S S, Bates S, Ginsberg J S. et al . Recurrent venous thrombosis and heparin therapy; an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med . 1999; 159 2029-2032
87 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med . 1997; 157 2562-2568
88 Raschke R A, Reilly B M, Guidry J R. et al . The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized, controlled trial. Ann Intern Med . 1993; 119 874-881
89 Merli G, Spiro T E, Olsson C-G. et al . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med . 2001; 134 191-202
90 Hainer J W, Barrett J S, Assaid C A. et al . Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost . 2002; 87 817-823
91 Moll S, Ortel T L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med . 1997; 127 177-185
92 Harrison L, Johnston M, Massicotte M P. et al . Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med . 1997; 126 133-136
93 Fihn S D, McDonell M, Martin D. et al . Risk factors for complications of chronic anticoagulation. Ann Intern Med . 1993; 118 511-520
94 Choueiri T, Deitcher S R. Why shouldn't we solely use warfarin to treat acute venous thrombosis?. Cleveland Clin J Med . 2002; 69 546-548
95 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost . 1994; 71 7-11
96 Pini M, Aiello S, Manotti C. et al . Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost . 1994; 72 191-197
97 Das S K, Cohen A T, Edmondson R A, Melissari E, Kakkar V V. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg . 1996; 20 521-527
98 Loaciuk S, Bielska-Falda H, Nosczyk W. et al . Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost . 1999; 81 26-31
99 Hull R D, Pineo G F, Mah A F, Brant R F. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium (Abstract 556). Blood . 2002; 100 148a
100 Gruel Y, Meyer G, Marjanovic Z. et al . Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer (Abst). Blood . 2001; 98 707a
101 Schulman S, Rhedin A S, Lindmarker P. et al . A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med . 1995; 332 1661-1665
102 Kearon C, Gent M, Hirsh J. et al . A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med . 1999; 340 901-907
103 Schulman S, Granqvist S, Holström M. et al . The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med . 1997; 336 393-398
104 Zacharski L R, Henderson W G, Rickles F R. et al . Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study Number 75. JAMA . 1981; 245 831-835
105 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of anticoagulation trial. N Engl J Med . 2000; 342 1953-1958
106 Simonneau G, Sors H, Charbonnier B. et al . A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med . 1997; 337 663-669
107 Goldhaber S Z. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost . 2001; 86 444-451
108 Arcasoy S M, Kreit J W. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest . 1999; 115 1695-1707
109 Konstantinides S, Tiede N, Geibel A. et al . Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol . 1998; 82 966-970
110 Kanter D S, Mikkola K M, Patel S R, Parker S Z, Golhaber S Z. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest . 1997; 111 1241-1245
111 Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncology patients: a phlebographic study. Eur J Radiol . 1995; 20 108-111
112 Monreal M, Raventos A, Lerma R. et al . Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost . 1994; 72 548-550
113 Ault M, Artal R. Upper extremity DVT: what is the risk?. Arch Intern Med . 1998; 158 1950-1952
114 Fraschini G, Jadeja J, Lawson M. et al . Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol . 1987; 5 672-678
115 Schwarz R E, Marrero A M, Conlon K C, Burt M. Inferior vena cava filters in cancer patients: indications and outcomes. J Clin Oncol . 1996; 14 652-657
116 Ihnat D M, Mills J L, Hughes J D. et al . Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?. J Vasc Surg . 1998; 28 800-807
117 Streift M B. Vena cava filters: a comprehensive review. Blood . 2000; 95 3669-3677
118 Athanasoulis C A, Kaufman J A, Halpern E F. et al . Inferior vena caval filters; a review of a 26-year single-centre clinical experience. Radiology . 2000; 21 54-66
119 Millward S F, Peterson R A, Moher D. et al . LGM (Vena Tech) vena caval filter: experience at a single institution. J Vasc Interv Radiol . 1994; 5 351-356
120 Spence L D, Gironta M G, Malde H M. et al . Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. Radiology . 1999; 210 53-58
121 Decousus H, Leizorovicz A, Parent F. et al . A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med . 1998; 338 409-415